Edap Tms S.A. Promotes From Within For CFO

Vaulx-En-Velin, France-based Edap Tms S.A., which makes therapeutic ultrasound technology, has promoted former Group Financial Control Manager and Finance Manager of the company’s French subsidiary Francois Dietsch to the position of chief financial officer (CFO).

“On behalf of the management team and board of directors, I would like to congratulate Francois on being promoted to CFO,” said CEO Marc Oczachowski. “In his ten years with the company he has been integral to the advancement of our finance team and the evolution of our financial reporting capabilities. He enters this role with a deep understanding of our business and familiarity with our internal controls and reporting systems, which he helped to design and implement. I am confident that these attributes will ensure a smooth transition and continuity and I look forward to working more closely with him as we continue to expand our global business ventures.”

Dietsch joined Edap in 2005 as internal audit and consolidation manager, leading the implementation of internal controls for Sarbanes-Oxley Compliance, consolidation of financial statements from the company’s subsidiaries and preparation of financial statements in accordance with U.S. GAAP (generally accepted accounting principles), including Edap’s annual report on Form 20-F. In 2012, he was promoted to the position of group financial control manager and finance manager of Edap’s French subsidiary where, in addition to his previous responsibilities, he managed accounting firm relationships at the subsidiary level and was the primary liaison between the company and its external auditors. He also managed the finance department at Edap France. Prior to joining EDAP he held finance positions at Valeo, a leading global supplier of components and systems to the automotive industry. He holds master’s degrees in management and corporate finance from Paris Dauphine University, France.

“This internal promotion will assure immediate transition and full continuity of all financial responsibilities at EDAP,” added Philippe Chauveau, Chairman of the Board. “As we continue to grow the Company, we are pleased to see talent and leadership emerge from within.”

Edap Tms markets Ablatherm for high-intensity focused ultrasound treatment of localized prostate cancer outside the United States. The company is currently pursuing a Direct De Novo petition together with a premarket approval for Ablatherm with the U.S. Food and Drug Administration.